CAS 1876467-74-1

Formule : C20H21N7O

InChI : InChI=1S/C20H21N7O/c1-13-12-28-10-9-27(13)18-11-15(17-5-8-23-26(17)2)14-3-6-21-20(19(14)24-18)16-4-7-22-25-16/h3-8,11,13H,9-10,12H2,1-2H3,(H,22,25)/t13-/m1/s1

Code InChI : YBXRSCXGRPSTMW-CYBMUJFWSA-N

SMILES : C[C@@H]1COCCN1C2=NC3=C(C=CN=C3C4=CC=NN4)C(=C2)C5=CC=NN5C

(R)-3-Methyl-4-(4-(1-Methyl-1H-Pyrazol-5-Yl)-8-(1H-Pyrazol-3-Yl)-1,7-Naphthyridin-2-Yl)Morpholine

CAS : 1876467-74-1

(R)-3-Methyl-4-(4-(1-Methyl-1H-Pyrazol-5-Yl)-8-(1H-Pyrazol-3-Yl)-1,7-Naphthyridin-2-Yl)Morpholine

Formule : C₂₀H₂₁N₇O

Degré de pureté : 98%

Masse moléculaire : 375.43

Ref: 54-OR1022999

BAY 1895344

CAS : 1876467-74-1

Formule : C₂₀H₂₁N₇O

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 375.4270

Ref: IN-DA01DDTF

Elimusertib

CAS : 1876467-74-1

Elimusertib

Formule : C₂₀H₂₁N₇O

Degré de pureté : ≥98%

Masse moléculaire : 375.43

Ref: 54-BUP12371

Elimusertib

CAS : 1876467-74-1

Elimusertib (BAY-1895344) is a potent, highly selective and orally available ATR inhibitor with an IC50 of 7 nM.Elimusertib shows potent anti-tumor efficacy in

Formule : C₂₀H₂₁N₇O

Degré de pureté : 98.72% - 99.98%

Couleur et forme : Yellow Solid

Masse moléculaire : 375.427

Ref: TM-T7318

Elimusertib

CAS : 1876467-74-1

(R)-3-Methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-3-yl)-1,7-naphthyridin-2-yl)morpholine

Formule : C₂₀H₂₁N₇O

Degré de pureté : 98%

Masse moléculaire : 375.43

Ref: IN-DG767537

BAY-1895344

Produit contrôlé

CAS : 1876467-74-1

Applications BAY-1895344 is a selective ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor used in the treatment of advanced hyperproliferative disease, prophylaxis, solid tumors and lymphomas.
References Wortmann, L., et al.: From PCT Int. Appl. (2016), WO 2016020320 A1 20160211

Formule : C₂₀H₂₁N₇O

Couleur et forme : Neat

Masse moléculaire : 375.43

Ref: TR-B118925

BAY-1895344

CAS : 1876467-74-1

BAY-1895344 is an inhibitor of the CDK4 and CDK6 proteins, which are tumor-promoting enzymes that regulate cell cycle progression. BAY-1895344 has been evaluated in clinical studies for the treatment of cancer with promising results. This drug was also shown to increase epidermal growth factor (EGF) levels in vitro and to promote autophagy, a process whereby cells degrade their own components. In addition, this compound has been shown to have a positive effect on telomere length and tumor response in patients with squamous carcinoma.

Formule : C₂₀H₂₁N₇O

Degré de pureté : Min. 95%

Masse moléculaire : 375.43 g/mol

Ref: 3D-BB178556